Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 10, 2023, reports a significant regulatory milestone for its oncology portfolio. The filing details the outcome of a US FDA Oncologic Drugs Advisory Committee (ODAC) vote regarding Jemperli (dostarlimab-gxly) for the treatment of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical development and regulatory progress.
Material Changes and Developments
- ODAC Vote: The US FDA ODAC voted 8 to 5 in support of GSK's proposed clinical trial design to evaluate Jemperli as a potential treatment for dMMR/MSI-H locally advanced rectal cancer.
- Regulatory Designation: The US FDA granted Fast Track designation to Jemperli for this patient population in January 2023.
- Trial Initiation: GSK is initiating a global, open-label, Phase II clinical trial to investigate dostarlimab-gxly as monotherapy, aiming to replace chemotherapy, radiation, and/or surgery.
- Strategic Goal: The company intends to use data from its proposed trial alongside data from an ongoing investigator-initiated trial at Memorial Sloan Kettering Cancer Center (MSK) to support a supplemental Biologics License Application (sBLA) for accelerated regulatory approval.
Outlook, Risks, and Management Commentary
Management Commentary: Hesham Abdullah, Senior Vice President of Global Head of Oncology Development, stated that the committee's positive vote reinforces plans to generate data for a future US regulatory submission. He highlighted the significant unmet medical needs in this population and the serious quality of life concerns associated with the current standard of care (neoadjuvant chemoradiotherapy followed by surgery).
Outlook: GSK aims for dostarlimab to become the backbone of its immuno-oncology R&D program. The application could be eligible for priority review if supported by clinical data at the time of submission.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the 2021 Form 20-F, Q4 2022 results, and impacts of the COVID-19 pandemic. Jemperli has not yet been approved anywhere in the world as monotherapy for treatment-naive patients with dMMR/MSI-H locally advanced rectal cancer.
Key Facts for Investor Verification
- Verify the specific endpoints of the proposed Phase II trial, primarily clinical complete response for 12 months (cCR12).
- Monitor the timeline for the submission of the supplemental Biologics License Application (sBLA) to the FDA.
- Track the progress of the concurrent investigator-initiated trial at Memorial Sloan Kettering Cancer Center (MSK) which will contribute data to the regulatory submission.
- Confirm the status of Jemperli's current approved indications (e.g., recurrent or advanced endometrial cancer) versus the new potential indication for rectal cancer.